E. Pianezzola

674 total citations
32 papers, 567 citations indexed

About

E. Pianezzola is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, E. Pianezzola has authored 32 papers receiving a total of 567 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Pharmacology and 8 papers in Oncology. Recurrent topics in E. Pianezzola's work include Cancer Treatment and Pharmacology (5 papers), Antibiotics Pharmacokinetics and Efficacy (5 papers) and Pharmacological Effects of Natural Compounds (4 papers). E. Pianezzola is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Antibiotics Pharmacokinetics and Efficacy (5 papers) and Pharmacological Effects of Natural Compounds (4 papers). E. Pianezzola collaborates with scholars based in Italy, United Kingdom and Netherlands. E. Pianezzola's co-authors include M. Strolin Benedetti, G. Ornati, E. Di Salle, T.R. Jeffry Evans, M. Lassus, R. Charles Coombes, Massimo Breda, E. Frigerio, E. Moro and Stefano Persiani and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, British Journal of Cancer and Journal of Chromatography A.

In The Last Decade

E. Pianezzola

31 papers receiving 525 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Pianezzola Italy 14 132 118 100 94 88 32 567
Norio Yasui Japan 19 51 0.4× 266 2.3× 155 1.6× 55 0.6× 123 1.4× 37 963
Anne Wu United States 13 47 0.4× 206 1.7× 78 0.8× 45 0.5× 131 1.5× 19 651
Wesley R. Anderson United States 16 62 0.5× 153 1.3× 100 1.0× 44 0.5× 21 0.2× 38 535
B. Nieuweboer Germany 13 41 0.3× 51 0.4× 29 0.3× 32 0.3× 53 0.6× 27 375
Kenji Kihira Japan 17 29 0.2× 216 1.8× 308 3.1× 43 0.5× 94 1.1× 88 828
Bruce W. Surber United States 17 36 0.3× 359 3.0× 238 2.4× 73 0.8× 73 0.8× 36 1.2k
Gustaf Plym Forshell Sweden 11 23 0.2× 117 1.0× 86 0.9× 33 0.4× 76 0.9× 21 432
E. Schillinger Germany 18 253 1.9× 243 2.1× 55 0.6× 31 0.3× 236 2.7× 58 1.1k
Julie A Gratton United Kingdom 8 25 0.2× 96 0.8× 63 0.6× 103 1.1× 16 0.2× 10 486
Armin Bruelisauer Switzerland 8 35 0.3× 120 1.0× 136 1.4× 25 0.3× 47 0.5× 10 474

Countries citing papers authored by E. Pianezzola

Since Specialization
Citations

This map shows the geographic impact of E. Pianezzola's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Pianezzola with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Pianezzola more than expected).

Fields of papers citing papers by E. Pianezzola

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Pianezzola. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Pianezzola. The network helps show where E. Pianezzola may publish in the future.

Co-authorship network of co-authors of E. Pianezzola

This figure shows the co-authorship network connecting the top 25 collaborators of E. Pianezzola. A scholar is included among the top collaborators of E. Pianezzola based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Pianezzola. E. Pianezzola is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Droz, J.P., A.-R. Hanauske, Jaap Verweij, et al.. (1998). Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients. British Journal of Cancer. 77(1). 139–146. 13 indexed citations
2.
Casati, Marco, et al.. (1997). Determination of turosteride, a new inhibitor of 5α-reductase, in human plasma by high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography B Biomedical Sciences and Applications. 688(1). 117–125. 2 indexed citations
3.
Marrari, P., E. Pianezzola, & M. Strolin Benedetti. (1996). Determination of tallimustine in human plasma by high-performance liquid chromatography. Journal of Chromatography B Biomedical Sciences and Applications. 677(1). 133–139. 3 indexed citations
4.
5.
6.
Benedetti, M. Strolin, et al.. (1995). An investigation of the pharmacokinetics and autoinduction of rifabuting metabolism in mice treated with 10 mg/kg/day six times a week for 8 weeks. Journal of Antimicrobial Chemotherapy. 36(1). 247–251. 5 indexed citations
7.
Pianezzola, E., et al.. (1994). Sensitive high-performance liquid chromatographic method for the determination of the three main metabolites of selegiline (l-deprenyl) in human plasma. Journal of Chromatography B Biomedical Sciences and Applications. 656(1). 251–258. 18 indexed citations
8.
Pianezzola, E., et al.. (1994). High-performance liquid chromatographic determination of FCE 24928, a new aromatase inhibitor, in human plasma. Journal of Chromatography A. 660(1-2). 293–298. 2 indexed citations
9.
10.
Persiani, Stefano, G. Sassolas, G. Piscitelli, et al.. (1994). Pharmacodynamics and Relative Bioavailability of Cabergoline Tablets vs Solution in Healthy Volunteers. Journal of Pharmaceutical Sciences. 83(10). 1421–1424. 21 indexed citations
11.
Breda, Massimo, E. Pianezzola, & M. Strolin Benedetti. (1993). Determination of exemestane, a new aromatase inhibitor, in plasma by high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography B Biomedical Sciences and Applications. 620(2). 225–231. 18 indexed citations
12.
Persiani, Stefano, et al.. (1992). Radioimmunoassay for the Synthetic Ergoline Derivative Cabergoline in Biological Fluids. Journal of Immunoassay. 13(3). 457–476. 10 indexed citations
13.
Pontiroli, Antonio E., Bruno Fattor, G. Pozza, et al.. (1992). Acipimox-induced facial skin flush: Frequency, thermographic evaluation and relationship to plasma acipimox level. European Journal of Clinical Pharmacology. 43(2). 145–148. 8 indexed citations
14.
Pianezzola, E., et al.. (1992). Determination of cabergoline in plasma and urine by high-performance liquid chromatography with electrochemical detection. Journal of Chromatography B Biomedical Sciences and Applications. 574(1). 170–174. 22 indexed citations
15.
Marrari, P., et al.. (1991). Pharmacokinetics of iododoxorubicin in the rat, dog, and monkey.. Drug Metabolism and Disposition. 19(5). 938–945. 4 indexed citations
16.
Benedetti, M. Strolin, et al.. (1991). Stereoselectivity of idarubicin reduction in various animal species and humans. Xenobiotica. 21(4). 473–480. 10 indexed citations
17.
Battaglia, R., et al.. (1990). Absorption, disposition and preliminary metabolic pathway of 14C-rifabutin in animals and man. Journal of Antimicrobial Chemotherapy. 26(6). 813–822. 32 indexed citations
18.
Pianezzola, E., et al.. (1989). Determination of the enantiomeric composition of salsolinol in biological samples by high-performance liquid chromatography with electrochemical detection. Journal of Chromatography B Biomedical Sciences and Applications. 495. 205–214. 24 indexed citations
19.
Benedetti, M. Strolin, et al.. (1989). Ratio of the R and S enantiomers of salsolinol in food and human urine. Journal of Neural Transmission. 77(1). 47–53. 56 indexed citations
20.
Pianezzola, E., et al.. (1986). Lack of pharmacokinetic interaction between cholestyramine and acipimox, a new lipid lowering drug.. British Journal of Clinical Pharmacology. 22(4). 496–497. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Norio Yasui Breakdown of academic impact, for papers by Anne Wu Breakdown of academic impact, for papers by Wesley R. Anderson Breakdown of academic impact, for papers by B. Nieuweboer Breakdown of academic impact, for papers by Kenji Kihira Breakdown of academic impact, for papers by Bruce W. Surber Breakdown of academic impact, for papers by Gustaf Plym Forshell Breakdown of academic impact, for papers by E. Schillinger Breakdown of academic impact, for papers by Julie A Gratton Breakdown of academic impact, for papers by Armin Bruelisauer
Rankless by CCL
2026